18 Fluorodeoxyglucose‐positron emission tomography/computed tomography features of suspected solitary pulmonary lesions in breast cancer patients following previous curative treatment

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background

Differentiating pulmonary metastasis from primary lung cancer can be challenging in patients with breast malignancy. This study aimed to characterize the imaging features of ¹⁸fluorodeoxyglucose‐positron emission tomography/computed tomography ( ¹⁸F‐FDG‐PET/CT) for distinguishing between these diseases.

Methods

We enrolled 52 patients who received curative treatment for breast cancer but later presented with suspected solitary pulmonary lesions (SPLs) and subsequently underwent ¹⁸F‐FDG‐PET/CT to investigate.

Results

Subsolid lesions, ill‐defined borders, lung lesions with negative maximum standardized uptake value, and lesions without ¹⁸F‐FDG‐PET/CT‐diagnosed hilar and/or mediastinal lymph nodes and pleural metastases were more likely to be associated with primary lung cancer.

Conclusions

CT border, FDG uptake, hilar and/or mediastinal lymph node metastasis, and pleural metastasis are potential markers for diagnosis.

Related collections

Most cited references 35

Record: found
Abstract: found
Article: not found

Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society.

Heber MacMahon, John Austin, Gordon Gamsu … (2005)

Lung nodules are detected very commonly on computed tomographic (CT) scans of the chest, and the ability to detect very small nodules improves with each new generation of CT scanner. In reported studies, up to 51% of smokers aged 50 years or older have pulmonary nodules on CT scans. However, the existing guidelines for follow-up and management of noncalcified nodules detected on nonscreening CT scans were developed before widespread use of multi-detector row CT and still indicate that every indeterminate nodule should be followed with serial CT for a minimum of 2 years. This policy, which requires large numbers of studies to be performed at considerable expense and with substantial radiation exposure for the affected population, has not proved to be beneficial or cost-effective. During the past 5 years, new information regarding prevalence, biologic characteristics, and growth rates of small lung cancers has become available; thus, the authors believe that the time-honored requirement to follow every small indeterminate nodule with serial CT should be revised. In this statement, which has been approved by the Fleischner Society, the pertinent data are reviewed, the authors' conclusions are summarized, and new guidelines are proposed for follow-up and management of small pulmonary nodules detected on CT scans.

0 comments Cited 246 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.

A. Buzdar, L Ziegler, G Hortobagyi … (1996)

To determine the long-term clinical course of patients with metastatic breast cancer (MBC) who achieved a complete remission with doxorubicin-alkylating agent-containing combination chemotherapy programs. To assess the long-term prognosis of MBC, we reviewed our experience with 1,581 patients treated on consecutive doxorubicin and alkylating agent-containing front-line treatment protocols between 1973 and 1982. Treatment was administered for a maximum duration of 2 years. Characteristics of long-term survivors were evaluated, and hazard rates for progression were calculated. From this group, 263 (16.6%) achieved complete responses (CR) and 49 (3.1%) remained in CR for more than 5 years. After a median duration of 191 months, 26 patients remain in first CR, four patients died in CR at times ranging from 118 to 234 months, 18 patients died of breast cancer, and one is alive with metastatic disease. Compared with the overall CR and total patient populations, the long-term CR group had more premenopausal patients, a younger median age, a lower tumor burden, and better performance status. The hazard function shows a substantial drop in risk of progression after approximately 3 years from initiation of therapy. Ten long-term CR patients developed second primary cancers: breast (3), ovary (2), pancreas (1), endometrium (1), colon (1), head and neck (1), and lung (1). Most patients with MBC treated with systemic therapies have only temporary responses to treatment, but some patients continue in CR following initial treatment. These data show that a small percentage of patients achieve long-term remissions with standard chemotherapy regimens. Remission consolidation strategies are needed.

0 comments Cited 80 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: not found
Article: not found

NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis.

A Heerdt, Nazanin Khakpour, Alan J. Garber … (2009)

0 comments Cited 52 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Lei Zhu:

ORCID: https://orcid.org/0000-0003-0213-3619

zhulei0519@163.com

Zhaoxiang Ye: yezhaoxiang@163.com

Wengui Xu: wenguixy@163.com

Xiaozhou Yu: yuxiaopiyxp@hotmail.com

Journal

Journal ID (nlm-ta): Thorac Cancer

Journal ID (iso-abbrev): Thorac Cancer

Journal ID (doi): 10.1111/(ISSN)1759-7714

Journal ID (publisher-id): TCA

Title: Thoracic Cancer

Publisher: John Wiley & Sons Australia, Ltd (Melbourne )

ISSN (Print): 1759-7706

ISSN (Electronic): 1759-7714

Publication date (Electronic): 21 March 2019

Publication date (Print): May 2019

Volume: 10

Issue: 5 ( doiID: 10.1111/tca.2019.10.issue-5 )

Pages: 1086-1095

Affiliations

[ ¹ ] Department of Molecular Imaging and Nuclear Medicine, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer Tianjin Medical University Cancer Institute and Hospital Tianjin China

[ ² ] Department of Radiology, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer Tianjin Medical University Cancer Institute and Hospital Tianjin China

[ ³ ] Department of Radiology Tianjin 4th Centre Hospital Tianjin China

[ ⁴ ] Department of Cardiovascular Surgery Tianjin Medical University General Hospital Tianjin China

Author notes

[*] [* ] Correspondence

Zhaoxiang Ye, Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China; Tianjin's Clinical Research Center for Cancer, Huan‐Hu‐Xi Road, Ti‐Yuan‐Bei, He Xi District, Tianjin 300060, China.

Tel: +86 22 2334 0123

Fax: +86 22 2353 7796

Email: yezhaoxiang@ 123456163.com

Wengui Xu, Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China; Tianjin's Clinical Research Center for Cancer, Huan‐Hu‐Xi Road, Ti‐Yuan‐Bei, He Xi District, Tianjin 300060, China.

Tel: +86 22 2334 0123

Fax: +86 22 2353 7796

Email: wenguixy@ 123456163.com

Xiaozhou Yu, Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China; Tianjin's Clinical Research Center for Cancer, Huan‐Hu‐Xi Road, Ti‐Yuan‐Bei, He Xi District, Tianjin 300060, China.

Tel: +86 22 2334 0123

Fax: +86 22 2353 7796

Email: yuxiaopiyxp@ 123456hotmail.com

[†]

These authors contributed equally to this work.

Author information

Lei Zhu https://orcid.org/0000-0003-0213-3619

Article

Publisher ID: TCA13049

DOI: 10.1111/1759-7714.13049

PMC ID: 6500976

PubMed ID: 30900387

SO-VID: c0e93747-24c2-4cb8-be2f-514d5dd2b65e

License:

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

History

Date received : 10 February 2019

Date revision received : 26 February 2019

Date accepted : 01 March 2019

Page count

Figures: 2, Tables: 5, Pages: 10, Words: 5946

Funding

Funded by: Science & Technology Development Fund of Tianjin Education Commission for Higher Education

Award ID: 2018KJ057

Award ID: 2018KJ061

Funded by: Tianjin Natural Science Fund

Award ID: 16JCZDJC35200

Award ID: 17JCYBJC25100

Funded by: Tianjin Science and Technology Fund

Award ID: 18PTZWHZ00100

Award ID: H2018206600

Funded by: National Natural Science Foundation of China

Award ID: 81601377

Award ID: 81501984

Custom metadata

source-schema-version-number 2.0

component-id tca13049

cover-date May 2019

details-of-publishers-convertor Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.2.1 mode:remove_FC converted:06.05.2019

Keywords: 18fluorodeoxyglucose‐positron emission tomography/computed tomography,breast cancer metastasis,lung cancer,solitary pulmonary lesion

Data availability:

Keywords: 18fluorodeoxyglucose‐positron emission tomography/computed tomography, breast cancer metastasis, lung cancer, solitary pulmonary lesion